SAM
ARRY

Senzar Asset Management’s Array Biopharma Inc ARRY Stock Holding History

Senzar Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-627,100
Closed -$4.23M – 40
2016
Q3 		$4.23M Buy
+627,100
New +$2.43M 1.09% 24

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Senzar Asset Management's ARRY Position: Q4 2016 in Review

Senzar Asset Management sold out of Array Biopharma Inc (ARRY) in Q4 2016, closing a stake of 627,100 shares — an estimated $4.23M sold.

Senzar Asset Management first reported a position in ARRY in Q3 2016 and held it in 1 quarter. The position peaked at $4.23M in Q3 2016. 167 funds tracked by Wall St. Rank hold ARRY as of Q4 2016.

  • Senzar Asset Management reported no remaining Array Biopharma Inc position as of Q4 2016 after selling out during the quarter.
  • Senzar Asset Management sold 627,100 Array Biopharma Inc shares in Q4 2016, an estimated $4.23M.
  • Senzar Asset Management first reported a position in Array Biopharma Inc in Q3 2016 and held it in 1 quarter.
  • Senzar Asset Management's Array Biopharma Inc position peaked at $4.23M in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2016.

Based on Senzar Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.